Quantitative MRI to automatically delineate intraprostatic tumor for radiation therapy

Active Project Grant Awarded Last action

Award ID
R01CA284172
Recipient
Awarding agency
Obligated
$1,353,393

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 42% complete
Originally
Place of performance
Irwindale, CA 91010, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Prostate cancer (PCA) is the most common cancer among men. Radiation therapy is an integral part of the standard of care for the treatment of PCA. Local recurrences of PCA after radiation therapy usually originate from the primary tumor site. A dose escalation to the clinically significant tumor (CST) foci in intermediate- and high-risk patients is reported to result in significantly improved biochemical disease-free survival (bdfs) without increasing radiation toxicity. Contouring of the intraprostatic tumor is currently based on multiparametric (MP-) magnetic resonance imaging (MRI) and the interpretation of the MRI results are based on prostate imaging reporting & data system (PI-rads). However, relatively large variability in performance of MP-MRI, including that of PI-rads, continue to pose barriers to identify clinically significant prostate tumor as treatment target and improve patient outcome. In this project, we propose to address the issues in both the MRI technique and scoring system aspects and develop a tool that can automatically delineate intraprostatic CST and be easily transferred to clinical use. To achieve this goal, in aim 1, we will build a quantitative MRI (qmri) toolset including magnetic resonance fingerprinting (MRF), arterial spin labeling (ASL), and diffusion- weighted MRI (DW-MRI). This toolset provides 3-dimensional high-resolution quantitative maps directly associated with tumor physiology and pathology features. In aim 2, based on the qmri output, we will develop an automated PCA tumor probability model and segmentation method that can automatically differentiate areas with clinically significant prostate cancer from other prostatic tissues. Aim 3 will be a validation study. We will validate the performance of our newly developed method against biopsy results and compare IT with the performance of physician's contour of CST foci based on MP-MRI and PI-rads as the current standard of care (SOC). We expect that the results of this project will provide a completely new set of qmri tools and tumor segmentation method that improves current SOC MP-MRI and PI-rads. This will allow US to accurately identify areas with clinically significant PCA in the intact prostate for boost irradiation, and achieve maximal local control in prostate cancer radiation therapy without increasing radiation toxicity.

Transactions

Action Obligated Date
Amendment $0
Amendment $648,830
Original award $704,563

Subawards

Subrecipient Amount Awarded
Carina Medical LLC At Carina Medical LLC, the following tasks are to be performed under the collaborative project “Quantitative MRI to automatically delineate intraprostatic… $174,518
Regents Of The University Of Michigan Under this Subaward Agreement, UCSD will: 1. Release both 2D and 3D Prostate MR Fingerprinting sequence developed at the University of Michigan to the City of… $315,266
The Regents Of The University Of California Participating as co-investigator: Jia Guo, PhD., UC Riverside Coordination with other co-PIs: Dr. Guo will communicate with the other two co-PIs: Dr. Kun Qing… $245,725

Quick answers

Who received award R01CA284172?

R01CA284172 was awarded to Beckman Research Institute Of The City Of Hope by National Cancer Institute (National Institutes of Health) on July 1, 2024.

How much is award R01CA284172 worth?

$1,353,393 has been obligated on R01CA284172.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login